Literature DB >> 19149765

Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach.

David A Davis1, Irene R Tebbs, Sarah I Daniels, Stephen J Stahl, Joshua D Kaufman, Paul Wingfield, Michael J Bowman, Jean Chmielewski, Robert Yarchoan.   

Abstract

Active-site inhibitors of HIV-1 PR (protease) block viral replication by preventing viral maturation. However, HIV-1 often develops resistance to active-site inhibitors through multiple mutations in PR and therefore recent efforts have focused on inhibiting PR dimerization as an alternative approach. Dimerization inhibitors have been identified using kinetic analysis, but additional characterization of the effect of these inhibitors on PR by physical methods has been difficult. In the present study, we identified a PR(MDR) (multi-drug-resistant HIV-1 PR) that was highly resistant to autoproteolysis. Using this PR and a novel size-exclusion chromatographic approach that incorporated fluorescence and MS detection, we were able to demonstrate inhibition of dimerization using P27 (peptide 27), a peptide dimerization inhibitor of PR previously identified on the basis of kinetic analysis. Incubation of PR(MDR) with P27, or other dimerization inhibitors, led to a dose- and time-dependent formation of PR monomers based on the change in elution time by size exclusion and its similar elution time to engineered forms of monomeric PR, namely PR(T26A) and glutathionylated PR. In contrast, incubation of PR(MDR) with a potent active-site inhibitor did not change the elution time for the PR(MDR) dimer. The monomeric PR induced by P27 had fluorescent characteristics which were consistent with unfolded PR. Structure-activity studies identified the active regions of P27 and experiments were performed to examine the effect of other dimerization inhibitors on PR. The present study is the first characterization of dimerization inhibition of PR(MDR), a prime target for these inhibitors, using a novel size-exclusion chromatographic approach.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19149765      PMCID: PMC2748811          DOI: 10.1042/BJ20082068

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  50 in total

1.  Reversible oxidation of HIV-2 protease.

Authors:  David A Davis; Fonda M Newcomb; Jackob Moskovitz; Henry M Fales; Rodney L Levine; Robert Yarchoan
Journal:  Methods Enzymol       Date:  2002       Impact factor: 1.600

2.  Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation.

Authors:  David A Davis; Cara A Brown; Fonda M Newcomb; Emily S Boja; Henry M Fales; Joshua Kaufman; Stephen J Stahl; Paul Wingfield; Robert Yarchoan
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Revisiting monomeric HIV-1 protease. Characterization and redesign for improved properties.

Authors:  John M Louis; Rieko Ishima; Issa Nesheiwat; Lewis K Pannell; Shannon M Lynch; Dennis A Torchia; Angela M Gronenborn
Journal:  J Biol Chem       Date:  2002-12-04       Impact factor: 5.157

Review 4.  Dimerization inhibitors of HIV-1 protease.

Authors:  Nicole Boggetto; Michèle Reboud-Ravaux
Journal:  Biol Chem       Date:  2002-09       Impact factor: 3.915

Review 5.  Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides.

Authors:  Michael J Bowman; Jean Chmielewski
Journal:  Biopolymers       Date:  2002       Impact factor: 2.505

6.  Folded monomer of HIV-1 protease.

Authors:  R Ishima; R Ghirlando; J Tözsér; A M Gronenborn; D A Torchia; J M Louis
Journal:  J Biol Chem       Date:  2001-10-11       Impact factor: 5.157

7.  Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice.

Authors:  Laura Romano; Giulietta Venturi; Saverio Giomi; Luigi Pippi; Pier E Valensin; Maurizio Zazzi
Journal:  J Med Virol       Date:  2002-02       Impact factor: 2.327

8.  HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase.

Authors:  D A Davis; F M Newcomb; J Moskovitz; P T Wingfield; S J Stahl; J Kaufman; H M Fales; R L Levine; R Yarchoan
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

9.  A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.

Authors:  Salman Muzammil; Patrick Ross; Ernesto Freire
Journal:  Biochemistry       Date:  2003-01-28       Impact factor: 3.162

10.  Activity and dimerization of human immunodeficiency virus protease as a function of solvent composition and enzyme concentration.

Authors:  S P Jordan; J Zugay; P L Darke; L C Kuo
Journal:  J Biol Chem       Date:  1992-10-05       Impact factor: 5.157

View more
  11 in total

1.  Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease.

Authors:  John M Louis; Rieko Ishima; Annie Aniana; Jane M Sayer
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

Review 2.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

3.  Understanding HIV-1 protease autoprocessing for novel therapeutic development.

Authors:  Liangqun Huang; Chaoping Chen
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

4.  Mechanism of dissociative inhibition of HIV protease and its autoprocessing from a precursor.

Authors:  Jane M Sayer; Annie Aniana; John M Louis
Journal:  J Mol Biol       Date:  2012-05-30       Impact factor: 5.469

5.  Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide.

Authors:  Sarah I Daniels; Erin E Soule; Katharine S Davidoff; John G Bernbaum; Duosha Hu; Kenji Maeda; Stephen J Stahl; Nicole E Naiman; Abdul A Waheed; Eric O Freed; Paul Wingfield; Robert Yarchoan; David A Davis
Journal:  FASEB J       Date:  2013-10-04       Impact factor: 5.191

6.  Real-time label-free measurement of HIV-1 protease activity by nanopore analysis.

Authors:  Liang Wang; Yujing Han; Shuo Zhou; Xiyun Guan
Journal:  Biosens Bioelectron       Date:  2014-06-25       Impact factor: 10.618

7.  Graphene oxide-based biosensing platform for rapid and sensitive detection of HIV-1 protease.

Authors:  Youwen Zhang; Xiaohan Chen; Golbarg M Roozbahani; Xiyun Guan
Journal:  Anal Bioanal Chem       Date:  2018-07-02       Impact factor: 4.142

8.  The initial step in human immunodeficiency virus type 1 GagProPol processing can be regulated by reversible oxidation.

Authors:  Sarah I Daniels; David A Davis; Erin E Soule; Stephen J Stahl; Irene R Tebbs; Paul Wingfield; Robert Yarchoan
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

9.  Current and Novel Inhibitors of HIV Protease.

Authors:  Jana Pokorná; Ladislav Machala; Pavlína Rezáčová; Jan Konvalinka
Journal:  Viruses       Date:  2009-12-11       Impact factor: 5.048

Review 10.  Development of peptide inhibitors of HIV transmission.

Authors:  Siyu Shi; Peter K Nguyen; Henry J Cabral; Ramon Diez-Barroso; Paul J Derry; Satoko M Kanahara; Vivek A Kumar
Journal:  Bioact Mater       Date:  2016-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.